Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Journal of the Endocrine Society|April 11, 2022
Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and ParagangliomasLauren Hassan Nelson, Harry Fuentes-Bayne, Jun Yin, et al.
Annals of Surgical Oncology|January 7, 2017
Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case SeriesVeljko Strajina, Benzon M Dy, David R Farley, et al.
Surgery|November 19, 2013
Operative intervention for recurrent adrenocortical cancerBenzon M Dy, Kevin B Wise, Melanie L Richards, et al.
Investigational New Drugs|June 8, 2019
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinomaHao Xie, Jun Yin, Manisha H Shah, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective StudyAshish V Chintakuntlawar, Kandelaria M Rumilla, Carin Y Smith, et al.
Haematologica|March 1, 2006
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-pointsAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2020
Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic TherapyNicole M Iñiguez-Ariza, Sina Jasim, Mabel M Ryder, et al.
Science Translational Medicine|January 4, 2013
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancerCrescent R Isham, Ayoko R Bossou, Vivian Negron, et al.
Thyroid : Official Journal of the American Thyroid Association|December 18, 2010
Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapyRobert L Foote, Julian R Molina, Jan L Kasperbauer, et al.
Investigational New Drugs|July 27, 2013
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignanciesShaji K Kumar, James Jett, Randolph Marks, et al.
Pageof 6